98 related articles for article (PubMed ID: 19942441)
1. Novel tumor-targeted RGD peptide-camptothecin conjugates: synthesis and biological evaluation.
Dal Pozzo A; Ni MH; Esposito E; Dallavalle S; Musso L; Bargiotti A; Pisano C; Vesci L; Bucci F; Castorina M; Foderà R; Giannini G; Aulicino C; Penco S
Bioorg Med Chem; 2010 Jan; 18(1):64-72. PubMed ID: 19942441
[TBL] [Abstract][Full Text] [Related]
2. Hydroxyethyl starch conjugates for improving the stability, pharmacokinetic behavior and antitumor activity of 10-hydroxy camptothecin.
Li G; Li Y; Tang Y; Zhang Y; Zhang Y; Yin T; Xu H; Cai C; Tang X
Int J Pharm; 2014 Aug; 471(1-2):234-44. PubMed ID: 24861941
[TBL] [Abstract][Full Text] [Related]
3. Application of human pancreatic carcinoid BON cells for receptor-targeted drug development.
Sun L; Morris LM; Luo J; Mackey LV; Leslie JS; Franko-Tobin LG; Fuselier JA; LePage KT; Coy DH
J Drug Target; 2011 Sep; 19(8):666-74. PubMed ID: 21083509
[TBL] [Abstract][Full Text] [Related]
4. Camptothecins in tumor homing via an RGD sequence mimetic.
Alloatti D; Giannini G; Vesci L; Castorina M; Pisano C; Badaloni E; Cabri W
Bioorg Med Chem Lett; 2012 Oct; 22(20):6509-12. PubMed ID: 22959246
[TBL] [Abstract][Full Text] [Related]
5. Camptothecin delivery systems: the utility of amino acid spacers for the conjugation of camptothecin with polyethylene glycol to create prodrugs.
Conover CD; Greenwald RB; Pendri A; Shum KL
Anticancer Drug Des; 1999 Dec; 14(6):499-506. PubMed ID: 10834271
[TBL] [Abstract][Full Text] [Related]
6. Preclinical to clinical development of the novel camptothecin nanopharmaceutical CRLX101.
Svenson S; Wolfgang M; Hwang J; Ryan J; Eliasof S
J Control Release; 2011 Jul; 153(1):49-55. PubMed ID: 21406204
[TBL] [Abstract][Full Text] [Related]
7. Enhancing the anticancer efficacy of camptothecin using biotinylated poly(ethylene glycol) conjugates in sensitive and multidrug-resistant human ovarian carcinoma cells.
Minko T; Paranjpe PV; Qiu B; Lalloo A; Won R; Stein S; Sinko PJ
Cancer Chemother Pharmacol; 2002 Aug; 50(2):143-50. PubMed ID: 12172980
[TBL] [Abstract][Full Text] [Related]
8. Synthesis and optimization of a bifunctional hyaluronan-based camptothecin prodrug.
Xu Z; Zheng W; Yin Z
Arch Pharm (Weinheim); 2014 Apr; 347(4):240-6. PubMed ID: 24402828
[TBL] [Abstract][Full Text] [Related]
9. Synthesis, biological studies and molecular dynamics of new anticancer RGD-based peptide conjugates for targeted drug delivery.
Gilad Y; Noy E; Senderowitz H; Albeck A; Firer MA; Gellerman G
Bioorg Med Chem; 2016 Jan; 24(2):294-303. PubMed ID: 26719208
[TBL] [Abstract][Full Text] [Related]
10. Direct fluorescence monitoring of the delivery and cellular uptake of a cancer-targeted RGD peptide-appended naphthalimide theragnostic prodrug.
Lee MH; Kim JY; Han JH; Bhuniya S; Sessler JL; Kang C; Kim JS
J Am Chem Soc; 2012 Aug; 134(30):12668-74. PubMed ID: 22642558
[TBL] [Abstract][Full Text] [Related]
11. Hydrophobically modified glycol chitosan nanoparticles-encapsulated camptothecin enhance the drug stability and tumor targeting in cancer therapy.
Min KH; Park K; Kim YS; Bae SM; Lee S; Jo HG; Park RW; Kim IS; Jeong SY; Kim K; Kwon IC
J Control Release; 2008 May; 127(3):208-18. PubMed ID: 18336946
[TBL] [Abstract][Full Text] [Related]
12. Nanocarrier improves the bioavailability, stability and antitumor activity of camptothecin.
Tang XJ; Han M; Yang B; Shen YQ; He ZG; Xu DH; Gao JQ
Int J Pharm; 2014 Dec; 477(1-2):536-45. PubMed ID: 25445532
[TBL] [Abstract][Full Text] [Related]
13. Conjugates of a novel 7-substituted camptothecin with RGD-peptides as α(v)β₃ integrin ligands: An approach to tumor-targeted therapy.
Dal Pozzo A; Esposito E; Ni M; Muzi L; Pisano C; Bucci F; Vesci L; Castorina M; Penco S
Bioconjug Chem; 2010 Nov; 21(11):1956-67. PubMed ID: 20949910
[TBL] [Abstract][Full Text] [Related]
14. A novel polyrotaxane-based intracellular delivery system for camptothecin: in vitro feasibility evaluation.
Moon C; Kwon YM; Lee WK; Park YJ; Chang LC; Yang VC
J Biomed Mater Res A; 2008 Jan; 84(1):238-46. PubMed ID: 17607767
[TBL] [Abstract][Full Text] [Related]
15. Camptothecin delivery systems: enhanced efficacy and tumor accumulation of camptothecin following its conjugation to polyethylene glycol via a glycine linker.
Conover CD; Greenwald RB; Pendri A; Gilbert CW; Shum KL
Cancer Chemother Pharmacol; 1998; 42(5):407-14. PubMed ID: 9771956
[TBL] [Abstract][Full Text] [Related]
16. Polymer-bound camptothecin: initial biodistribution and antitumour activity studies.
Caiolfa VR; Zamai M; Fiorino A; Frigerio E; Pellizzoni C; d'Argy R; Ghiglieri A; Castelli MG; Farao M; Pesenti E; Gigli M; Angelucci F; Suarato A
J Control Release; 2000 Mar; 65(1-2):105-19. PubMed ID: 10699275
[TBL] [Abstract][Full Text] [Related]
17. Dual sensitive and temporally controlled camptothecin prodrug liposomes codelivery of siRNA for high efficiency tumor therapy.
Li Y; Liu R; Yang J; Ma G; Zhang Z; Zhang X
Biomaterials; 2014 Dec; 35(36):9731-45. PubMed ID: 25189519
[TBL] [Abstract][Full Text] [Related]
18. Lactone Stabilization is Not a Necessary Feature for Antibody Conjugates of Camptothecins.
Lau UY; Benoit LT; Stevens NS; Emmerton KK; Zaval M; Cochran JH; Senter PD
Mol Pharm; 2018 Sep; 15(9):4063-4072. PubMed ID: 30067902
[TBL] [Abstract][Full Text] [Related]
19. Novel anti-tumor strategy: PEG-hydroxycamptothecin conjugate loaded transferrin-PEG-nanoparticles.
Hong M; Zhu S; Jiang Y; Tang G; Sun C; Fang C; Shi B; Pei Y
J Control Release; 2010 Jan; 141(1):22-9. PubMed ID: 19735683
[TBL] [Abstract][Full Text] [Related]
20. A new targeted delivery approach by functionalizing drug nanocrystals through polydopamine coating.
Zhan H; Jagtiani T; Liang JF
Eur J Pharm Biopharm; 2017 May; 114():221-229. PubMed ID: 28161549
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
